EA200702332A1 - Пролекарства n-тиазол-2-илбензамидных производных - Google Patents

Пролекарства n-тиазол-2-илбензамидных производных

Info

Publication number
EA200702332A1
EA200702332A1 EA200702332A EA200702332A EA200702332A1 EA 200702332 A1 EA200702332 A1 EA 200702332A1 EA 200702332 A EA200702332 A EA 200702332A EA 200702332 A EA200702332 A EA 200702332A EA 200702332 A1 EA200702332 A1 EA 200702332A1
Authority
EA
Eurasian Patent Office
Prior art keywords
ylbenzamidine
thiazol
chemistry processes
compounds
chemistry
Prior art date
Application number
EA200702332A
Other languages
English (en)
Inventor
Гитте Миккельсен
Анетте Гравен Самс
Бенни Банг-Андерсен
Могенс Ларсен
Original Assignee
Х. Лундбекк А/С
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Х. Лундбекк А/С filed Critical Х. Лундбекк А/С
Publication of EA200702332A1 publication Critical patent/EA200702332A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Изобретение относится к соединениям формулы I, охарактеризованным в формуле изобретения. Данные соединения являются пролекарствами лигандов рецепторов Aс улучшенной растворимостью в воде, и пригодны для лечения неврологических и психиатрических заболеваний, в процесс которых вовлечены рецепторы A.
EA200702332A 2005-04-25 2006-04-24 Пролекарства n-тиазол-2-илбензамидных производных EA200702332A1 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DKPA200500594 2005-04-25
DKPA200501331 2005-09-26
DKPA200600445 2006-03-28
PCT/DK2006/000212 WO2006114093A1 (en) 2005-04-25 2006-04-24 Pro-drugs of n-thiazol-2yl-benzamide derivatives

Publications (1)

Publication Number Publication Date
EA200702332A1 true EA200702332A1 (ru) 2008-04-28

Family

ID=36617296

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200702332A EA200702332A1 (ru) 2005-04-25 2006-04-24 Пролекарства n-тиазол-2-илбензамидных производных

Country Status (13)

Country Link
EP (1) EP1877391A1 (ru)
JP (1) JP2008538772A (ru)
KR (1) KR20080000607A (ru)
AR (1) AR054032A1 (ru)
AU (1) AU2006239642A1 (ru)
BR (1) BRPI0609565A2 (ru)
CA (1) CA2606011A1 (ru)
EA (1) EA200702332A1 (ru)
IL (1) IL186143A0 (ru)
MX (1) MX2007012552A (ru)
NO (1) NO20076063L (ru)
TW (1) TW200720264A (ru)
WO (1) WO2006114093A1 (ru)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010140339A1 (ja) * 2009-06-01 2010-12-09 武田薬品工業株式会社 複素環化合物
MY159059A (en) * 2010-12-20 2016-12-15 Glenmark Pharmaceuticals Sa 2-amino-4-arylthiazole compounds as trpa1 antagonists

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9823871D0 (en) * 1998-10-30 1998-12-23 Pharmacia & Upjohn Spa 2-Amino-thiazole derivatives, process for their preparation, and their use as antitumour agents
DE10348022A1 (de) * 2003-10-15 2005-05-25 Imtm Gmbh Neue Dipeptidylpeptidase IV-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen
TW200524887A (en) * 2003-10-27 2005-08-01 Lundbeck & Co As H N-thiazol-2-yl-benzamide derivatives
US20080312435A1 (en) * 2004-11-15 2008-12-18 Taisho Pharmaceutical Co., Ltd. Imine Compound

Also Published As

Publication number Publication date
KR20080000607A (ko) 2008-01-02
NO20076063L (no) 2007-11-26
MX2007012552A (es) 2007-11-16
TW200720264A (en) 2007-06-01
AU2006239642A1 (en) 2006-11-02
IL186143A0 (en) 2008-01-20
AR054032A1 (es) 2007-05-30
JP2008538772A (ja) 2008-11-06
WO2006114093A1 (en) 2006-11-02
BRPI0609565A2 (pt) 2011-10-18
EP1877391A1 (en) 2008-01-16
CA2606011A1 (en) 2006-11-02

Similar Documents

Publication Publication Date Title
EA200900048A1 (ru) Новые карбонилированные (аза)циклогексаны в качестве лигандов d3 рецептора дофамина
EA200501504A1 (ru) Лиганды каннабиноидных рецепторов и их применение
CR8644A (es) Compuestos de imidazol para el tratamiento de transtornos neurodegenerativos
MA34284B1 (fr) Indoles
EA201070158A1 (ru) Сульфонамиды в качестве trpm8 модуляторов
ES2338590T3 (es) Procedimiento regioselectivo de preparacion de benzoimidazoltiofenos.
EA200501771A1 (ru) Лиганды каннабиноидных рецепторов и их применения
TNSN07325A1 (en) Pgd2 receptor antagonists for the treatment of inflammatory diseases
SE0303180D0 (sv) Novel compounds
SE0302232D0 (sv) Novel Compounds
EA200801362A1 (ru) Пиримидинил бензотиофеновые соединения
ATE448230T1 (de) Für die behandlung von obesitas geeignete tricyclische amidderivate
CY1107956T1 (el) Χρηση υποκατεστημενων 2-αμινοτετραλινιων για την προληπτικη αντιμετωπιση της νοσου του παρκινσον
ATE438632T1 (de) Aryl-4-ethinylisoxazolderivate
EA201170154A1 (ru) Производные пиридинопиридинонов, способ их получения и применение в терапии
MA32505B1 (fr) 5-alcynyl-pyrimidines
EA201171211A1 (ru) Производные оксадиазола
EA200900090A1 (ru) Бензиламины, способ их получения и их применение в качестве противовоспалительных средств
DE602006010738D1 (de) Pyrroloä2,3-cüpyridinderivate
ATE520651T1 (de) Substituierte phenylmethylbicyclocarbonsäureamidverbindungen
CR8669A (es) Compuestos de sulfonamidas para el tratamiento de trastornos neurodegenerativos
TW200633977A (en) Novel process for the manufacture of 3-pyrrolidin-2-yl-propionic acid derivatives
NO20074047L (no) Ny fremgangsmate for fremstilling av substituerte indoler
EA201170344A1 (ru) Азаиндольные ингибиторы iap
PL1723140T3 (pl) Sposób wytwarzania inhibitorów tryptazy